EQS-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS) 26-Oct-2023 / 08:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS) 03-Feb-2022 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) 04-Feb-2021 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) 29-Oct-2020 / 07:01 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Disposal Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion 24-Aug-2020 / 09:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Takeda to Divest its Japan Consumer Health...
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) 31-Jul-2020 / 08:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) ('Takeda') heeft vandaag de voltooiing aangekondigd van de eerder aangekondigde verkoop van een portfolio van geselecteerde vrij verkrijgbare (OTC-) geneesmiddelen en receptgeneesmiddelen in een aantal landen in het Nabije Oosten, Midden-Oosten en Afrika binnen zijn Growth and Emerging Markets Business Unit (GEM BU) aan Acino voor een totale waarde van meer dan 200 miljoen dollar. De desinvesteringsovereenkomst werd voor het eerst...
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) ('Takeda') heeft vandaag aangekondigd dat het een overeenkomst is aangegaan om een portfolio van geselecteerde niet-kernproducten exclusief in Latijns-Amerika te verkopen aan Hypera S.A. ('Hypera Pharma'), het grootste farmaceutische bedrijf van Brazilië met een leidende positie op het gebied van merkrecepten, consumentengezondheid en generieke merkproducten, voor een totale waarde van 825 miljoen dollar. Het portfolio omvat vrij...
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (« Takeda ») a annoncé aujourd'hui la signature de la vente annoncée précédemment d'un portefeuille contenant certains actifs pharmaceutiques OTC et médicaments prescrits sur ordonnance dans plusieurs pays du Proche-Orient, du Moyen-Orient et d'Afrique au sein de son unité commerciale Croissance et Marchés Émergents (BU GEM ) à Acino pour une valeur totale supérieure à 200 millions de dollars. L'accord de cession a été...
Takeda Pharmaceutical Company Limited ( Bolsa de Valores de Tokio:4502/Bolsa de Valores de Nueva York:TAK ) (“Takeda”) anunció hoy la finalización de la previamente anunciada venta a Acino de una cartera de activos farmacéuticos de venta libre y con receta en una serie de países de Oriente Próximo, Oriente Medio y África dentro de su unidad de negocios de países emergentes, por un valor total que supera los 200 millones de dólares. El acuerdo de venta se anunció por primera vez en...
Takeda Pharmaceutical Company Limited ( Bolsa de Valores de Tokio:4502/Bolsa de Valores de Nueva York:TAK ) (“Takeda”) anunció hoy que firmó un acuerdo para vender una cartera de productos seleccionados y no centrales exclusivamente en América Latina a Hypera S.A. (“Hypera Pharma”), la empresa farmacéutica más grande de Brasil con una posición líder en recetas de marca, salud del consumidor y genéricos de marca, por un valor total de 825 millones de dólares. La cartera incluye...
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (« Takeda ») a annoncé aujourd'hui avoir signé un accord visant la cession, à Hypera S.A. (« Hypera Pharma »), la plus importante société pharmaceutique du Brésil, qui se trouve en tête du marché des prescriptions de produits de marque, de santé grand public et de génériques, d'un portefeuille de certains produits non essentiels exclusivement en Amérique latine, pour une valeur totale de 825 millions de dollars. Ce...
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa countries within its Growth and Emerging Markets Business Unit (GEM BU) to Acino for a total value in excess of $200 million USD. The divestment agreement was first announced in October 2019. The transaction includes...
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A. (“Hypera Pharma”), Brazil’s largest pharmaceutical company with a leading position in branded prescriptions, consumer health and branded generics, for a total value of $825M USD. The portfolio includes over-the-counter and prescription pharmaceutical products sold in...
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS) 04-Feb-2020 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Annual Results Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2019 (IFRS) 31-Oct-2019 / 07:30 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. October 31, 2019 Notice of the Revised Forecast of...
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Miscellaneous Takeda Pharmaceutical Company Limited: Takeda Issues US Recall of NATPARA(R) (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate 06-Sep-2019 / 08:15 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Takeda Issues US...
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Quarter Results/Change in Forecast Takeda Pharmaceutical Company Limited: Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year 31-Jul-2019 / 08:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Takeda Reports Strong First...
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Annual Results Takeda Pharmaceutical Company Limited: Revised Forecast of Consolidated Financials for FY2018 (IFRS) 25-Apr-2019 / 08:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. News Release April 25, 2019 Revised Forecast of Consolidated Financials...
Takeda annonce lors du congrès annuel 2019 de l’EAHAD les résultats de l’essai PROPEL de phase IIIb/IV – une étude de prophylaxie guidée par la pharmacocinétique randomisée, première du genre, évaluant des niveaux supérieurs de facteur VIII dans l’hémophilie A Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (« Takeda »), le leader biotechnologique mondial dans le domaine des maladies rares, a annoncé aujourd’hui les résultats de son essai clinique de phase...